1O Efficacy and safety of setidegrasib in patients (pts) with advanced NSCLC with KRAS G12D mutation

Conclusions: This is the first prospective phase III trial showing osi plus CTx significantly prolongs PFS versus osi monotherapy in advanced EGFRm NSCLC with TP53 co-mutations.These findings suggest that this high-risk population might benefit more from combination therapy.Clinical trial identification: NCT04695925.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-03-17
DOI
https://doi.org/10.1016/j.esmoop.2026.106308
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

1O Efficacy and safety of setidegrasib in patients (pts) with advanced NSCLC with KRAS G12D mutation

Daniel Morgensztern, Aditya Shetty, P. LoRusso, C.M. Lovly et al.
ESMO Open
Lung Cancer Treatments and Mutations
article

1O Efficacy and safety of setidegrasib in patients (pts) with advanced NSCLC with KRAS G12D mutation

Daniel Morgensztern, Aditya Shetty, P. LoRusso, C.M. Lovly, Shilpa Kadam, H-J. Lee, B. You, H. Hayashi, L. Paz-Ares, A. Hollebecque, C. Fountzilas, M. Jung, J.W. Goldman, T. Macarulla Mercade, A. Italiano, S-W. Kim, T. Nishina, A. Spira, P. Cassier, S. Gill
article en

Abstract

Conclusions: This is the first prospective phase III trial showing osi plus CTx significantly prolongs PFS versus osi monotherapy in advanced EGFRm NSCLC with TP53 co-mutations.These findings suggest that this high-risk population might benefit more from combination therapy.Clinical trial identification: NCT04695925.

ESMO OpenVol. 11
Roswell Park Comprehensive Cancer Center (US), Université de Bordeaux (FR), Lyon College (US), Yonsei University (KR), Washington University in St. Louis (US), Asan Medical Center (KR), Institut Gustave Roussy (FR), Yale Cancer Center (US), Yale University (US), University of Santa Monica (US), Hospices Civils de Lyon (FR), Hospital Universitario 12 De Octubre (ES), Centre Léon Bérard (FR), Virginia Cancer Specialists (US), Vall d'Hebron Hospital Universitari (ES), Washington University Medical Center (US), Shikoku Cancer Center (JP), Astellas Pharma (United States) (US), Vanderbilt University Medical Center (US), Kindai University (JP)
Openalex Percentile: Top 20%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

1O Efficacy and safety of setidegrasib in patients (pts) with advanced NSCLC with KRAS G12D mutation — Daniel Morgensztern, Aditya Shetty, et al. · ESMO Open (2026) | TGRS Research Map | TGRS